Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Dedicare AB (publ) is a Sweden-based recruitment and staffing company specializing in the healthcare, life science, education, and social work sectors. Incorporated in 1995 and headquartered in Stockholm, it provides essential workforce solutions across Sweden, Norway, Finland, the United Kingdom, and Denmark. The company recruits and contracts highly skilled professionals, including doctors and nurses for medical services; social secretaries, family therapists, psychologists, and psychosocial support staff; as well as educators, assistants, and preschool personnel. In life sciences, it offers recruitment and interim management for pharmaceutical, biotechnology, and medical technology fields. With approximately 1,061 employees, Dedicare AB (publ) plays a vital role in addressing staffing needs in critical public and private sectors, supporting healthcare delivery, educational institutions, and innovative research environments. Led by CEO Bard Kristiansen, it operates within the industrials sector, focusing on employment services to bridge talent gaps in specialized industries.
kr 46.15
+kr 1.85 (+4.18%)
Price from 8 days ago
Operating margin is thin at 2.57%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 15.4% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 18% versus the prior year, cash generation momentum has weakened. ROIC dropped from 11.92% to 8.57%, capital efficiency is deteriorating.
13.0x earnings, 26.0x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 1.47B
▼ -15.4% YoY
Net Income (TTM)
kr 34M
▼ -29.7% YoY
Op. Margin
2.50%
▼ -0.7pp YoY
ROIC
8.57%
▼ -3.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 17M
▼ -17.7% YoY
Op. Cash Flow (TTM)
kr 17M
▼ -18.6% YoY
Net Debt
-kr 53M
Net Cash Position
Cash & Equiv.
kr 99M
3Y CAGR: -6.3%
3Y CAGR: -13.7%
Continue Research
At a P/E of 13.0 and a price-to-free-cash-flow of 26.0, Dedicare AB (publ) (DEDI.XSTO) trades above a two-stage DCF intrinsic value of about SEK 36.29 per share, so at SEK 46.15 the stock looks overvalued (21.4% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Dedicare AB (publ) scores 38/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 5.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 36.29 per share for DEDI.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 27.22. At today's SEK 46.15, that puts the stock about 21.4% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Dedicare AB (publ) scores 38 out of 100 on Intrinsiqq's quality score, passing 3 of 8 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a 2.5% operating margin and a 8.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
Yes, Dedicare AB (publ) pays a regular dividend of about SEK 2.50 per share per year (typically in quarterly installments), a yield of roughly 5.4% at the current price. That is a payout ratio of about 70.1% of earnings, so the dividend is covered, with less cushion. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For DEDI.XSTO's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. DEDI.XSTO currently trades above its estimated intrinsic value and scores 38/100 on quality (lower-quality). It also yields about 5.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.